About the cost of opposing the Goumarin-inhibitor theory:Reply by Hemker, H.C.
  
 
About the cost of opposing the Goumarin-inhibitor
theory
Citation for published version (APA):
Hemker, H. C. (1983). About the cost of opposing the Goumarin-inhibitor theory: Reply. Thrombosis and
Haemostasis, 49(3). https://doi.org/10.1055/s-0038-1657374
Document status and date:
Published: 28/06/1983
DOI:
10.1055/s-0038-1657374
Document Version:
Other version
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Jun. 2020
Reprint
Thrombosis
and Haemostasis
formerly Thrombosis et Diathesis Haemorrhagica
founded by R.Jrirgens, E. Deutsch and F. Kol ler
Journal of the International Society on Thrombosis and Haemostasis
No.3  Vo l .49
June 28, 1983
Editor:
F. Duckert, Basel
Editorial Board: U. Abildgaard, Norway ' E. A. Beck, Switzerland . J. P. Cazenave, France . P. J, Gaffney, UK ' A. Henschen,
FRG ' T. B. L. Kirkwood, UK ' J. M. McDonagh, USA . S. Magnusson, Denmark . A. J. Marcus, USA . V. J. Marder, USA
D. M6nach6-Aronson, USA ' M. A. Packham, Canada ' C. R. Rizza, UK ' H. J. Weiss, USA . M. B. Zucker, USA
F. K. Schattauer Verlag . Stuttgart - New York
Thromb Haemostas (Stuttgart)
Thromb Haemostas (Stuttgart) 49 (3) 240 (1983)
About the Cost of Opposing the Goumarin-lnhibitor Theory - Reply
Dear Sir,
At this moment it is common knowledge that vitamin K takes
part in an enzymatic carboxylation that causes a postribosomal
modification of several proteins in several organs. The best known
proteins are the coagulation factors II, VII, IX, X and protein C,
produced in the liver and shed out in the plasma. It also is known
to everybody familiar with the field that in certain species (man,
cow) vitamin K deficiency or administration of coumarin congen-
ers will cause the uncarboxylated factors to circulate whereas in
other species (rat, rabbit, chicken!) no such uncarboxylated
proteins have been demonstrated in the plasma although they do
pile up in the liver.
The question Dr. Girolami is interested in is whether or not
one of these acarboxfactors does inhibit the Thrombotest time.
This is a question of particular interest to me as we reported this
inhibition for the first time in 1963. We recognised it on basis of
the disproportionally long Thrombotest times of undiluted anti-
coagulated plasma (the PIVKA phenomenon).
On basis of these findings we were the first to postulate that
vitamin K would act at a postribosomal level and that abnormal
factors would circulate in man under conditions of vitamin K
deficiency or the intake of coumarin derivatives. At this moment I
do not feel that my early observations are mistaken. Not because
they led to a hypothesis that proved to be fruitful as a basis for
further research and until now goes unchallenged but rather
because they have been repeated and confirmed numerous times
in other laboratories as well as in our own. I am completely aware
of the fact that this implies that I have reasons not to accept the
evidence brought forward by Dr. Girolami. (To cite one example:
it is unacceptable to use as evidence against the PIVKA inhibition
the absence of coumarin induced inhibition in the chicken if it is
known that in this species the uncarboxylated factors are not
demonstrated in the plasma). If I, like Dr. Girolami, would be
unable to repeat the experiments from another lab, I would be
reluctant to use words like fraud and dishonesty.
I would prefer to try and repeat, confirm or falsify the original
results in a joint venture and thus arrive at a common opinion
between the two of us before trying to convince the rest of the
world.
Completely unrelated to the main question but frequently
appearing as a confounding issue is the problem of the importance
of "inhibition sensitivity" of the thromboplastins. In our experi
ence such differences do exist. They are at the basis of the fact
that the "percentage of coagulation activity" obtained with
different thromboplastins may differ considerably. Thrombotest
appears to be especially sensitive as witnessed by the well-known
fact that e.g. "1.0Vo Thrombotest" is found with the vitamin K
dependent factors at levels of around 20Vo etc. The practical
importance of this fact is that it makes comparison of thrombo-
plastins difficult. Nobody has ever shown that the PIVKA-
phenomenon is of any clinical importance and I agree with Dr.
Girolami that inhibitor sensitivity cannot be used as an argument
in favour of one type of thromboplastin over the other. With the
permission of the editor I will end this discussion with a personal
note.
I believe that the personal involvement of researchers is the
spice in science. I also believe that any spice added in excess
makes any dish unpalatable. I fear that Dr. Girolami, in adding his
favorite flavour to this discussion, has gone as far as the limits of
good taste allow.
I feel that the only step that can be taken from here on is to
invite Dr. Girolami to my lab and I do hope that the next paper on
this subject will be signed by him and me together no matter
whether it refutes or reconfirms my original observations.
H. C. Hemker
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